Precision Test For Breast Cancer Treatment Remains Imprecise : Shots : npr

As it stated in npr

Precision Test For Breast Cancer Treatment Remains Imprecise : Shots

Precision Test For Breast Cancer Treatment Remains Imprecise : Shots

Study Of Breast Cancer Treatment Reveals Paradox Of Precision MedicineEnlarge this image toggle caption Voisin/Phanie/Science Source Voisin/Phanie/Science SourceA major study about the best way to treat early-stage breast cancer reveals that "precision medicine" doesn't provide unambiguous answers about how to choose the best therapy."Precision doesn't mean certainty," says David Hunter, a professor of cancer prevention at Harvard's T.H.Chan School of Public Health.That point is illustrated in a large study published Wednesday in the New England Journal of Medicine, involving decisions about chemotherapy.


by the same token on wsav

2016 Making Strides Against Breast Cancer kickoff

2016 Making Strides Against Breast Cancer kickoff

We've seen major progress in the fight against one of the most common cancers in women– breast cancer.Today, survivors and their families joined the American Cancer Society to set the stage for the Making Strides Against Breast Cancer walk slated for October 30th.Among these 8 survivors honored, about 40 birthdays have been celebrated since their diagnosis.That's motivation for these team captains and fundraisers to ensure no one walks alone in their journey.


coupled with nejm

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer — NEJM

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer — NEJM

Background The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer.We sought to provide prospective evidence of the clinical utility of the addition of the 70-gene signature to standard clinical–pathological criteria in selecting patients for adjuvant chemotherapy.Methods In this randomized, phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their genomic risk (using the 70-gene signature) and their clinical risk (using a modified version of Adjuvant!Women at low clinical and genomic risk did not receive chemotherapy, whereas those at high clinical and genomic risk did receive such therapy.